The pooled evidence concerns kidney outcomes with semaglutide in the people enrolled in three trials. The randomized trials were pooled at participant level, covering 30,787 people over more than three years. The primary kidney composite favored semaglutide. There were 973 events against 1,134, a hazard ratio of 0.84.
That composite counts cardiovascular death as one of four components. Strip it out and the kidney-only result holds. It ran 347 events against 416, hazard ratio 0.80.
The guide to GLP-1 medicines after a kidney transplant summarizes observational studies in transplant recipients. A separate FLOW analysis broke down the result by stage of chronic kidney disease [2].
A German cost-effectiveness model projected the greatest gain in quality-adjusted survival for tirzepatide and the highest direct costs among the options modeled [3]. Those projections reflect German health-system assumptions and do not establish clinical superiority in a head-to-head kidney trial.
What was pooled
Participant-level data from SELECT, FLOW and SOUL, prespecified rather than assembled afterward. [1] One trial enrolled people with chronic kidney disease and used 1.0 mg semaglutide by weekly injection. One enrolled people with established atherosclerotic cardiovascular disease and used 2.4 mg weekly by injection. The third enrolled adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both. It used 14 mg of oral semaglutide daily. Together, 30,787 participants with a mean follow-up between 39.5 and 47.5 months.
What the primary outcome measured
The primary endpoint was a composite. A persistent 50% or greater fall in kidney filtration, kidney failure, kidney-related death, or cardiovascular death. On that, 973 first events occurred on semaglutide against 1,134 on placebo. The hazard ratio was 0.84, 95% CI 0.77 to 0.91.
Cardiovascular death contributed to the first-event count alongside the kidney outcomes. The researchers also analyzed a narrower composite that excluded cardiovascular death.
What the pooled estimate can tell us
The pooled hazard ratio summarizes three trials with different enrollment criteria, doses and routes. It does not establish an equivalent kidney benefit for oral and injected semaglutide.
It matters commercially because the two formats are not priced alike here. Take only the 14 sellers publishing a figure for both, read November 2026. The tablet runs a median of $34 more a month than the injection. Of those sellers, 8 charge more for it. Whether that gap reflects anything about outcomes is exactly what nobody has tested, and the price check shows the current spread.
Who funded it, and who it describes
Novo Nordisk funded the pooled analysis. The researchers specified the analysis in advance.
The population is people with cardio-kidney-metabolic disease — kidney disease or established cardiovascular disease, mostly with diabetes. If you are buying for weight loss, this describes somebody else’s risk profile. To understand how baseline risk changes the expected benefit, see how many people have to be treated for one event to be prevented. That number depends on the population and follow-up period.